

Neuroendocrine Tumors Therapeutic Pipeline Market Review, H2 2016

Neuroendocrine Tumors Treatment Pipeline Review H2 2016

PUNE, INDIA, October 14, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Neuroendocrine Tumors](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/535878-neuroendocrine-tumors-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

major and minor projects

- The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=535878

Table of Contents

Table of Contents 2

Introduction 5

Neuroendocrine Tumors Overview 6

Therapeutics Development 7

Neuroendocrine Tumors - Therapeutics under Development by Companies 9

Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes 11

Neuroendocrine Tumors - Pipeline Products Glance 12

Neuroendocrine Tumors - Products under Development by Companies 15

Neuroendocrine Tumors - Products under Investigation by Universities/Institutes 18

Neuroendocrine Tumors - Companies Involved in Therapeutics Development 19

Neuroendocrine Tumors - Therapeutics Assessment 54

Drug Profiles 66

Neuroendocrine Tumors - Recent Pipeline Updates 186

Neuroendocrine Tumors - Dormant Projects 288

Neuroendocrine Tumors - Discontinued Products 289

Neuroendocrine Tumors - Product Development Milestones 290

Appendix 297

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H1 2016 13

Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Number of Products under Development by Companies, H1 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
...Continued

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H1 2016 13
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 60
Number of Products by Top 10 Targets, H1 2016 61
Number of Products by Stage and Top 10 Targets, H1 2016 61
...Continued

Access Report @ <https://www.wiseguyreports.com/reports/535878-neuroendocrine-tumors-pipeline-review-h1-2016>

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.